X

Eli Lilly and Company (LLY) Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

Newsdesk: